(Formerly known as, Sotac Pharmaceuticals Private Limited) Registered Office : Plot No. PF/21, Nr. Acme Pharma, Opp. Teva Pharma, Sanand GIDC - II, Sanand, Ahmedabad – 382110, Gujarat (INDIA)

SOTAC PHARMACEUTICALS LIMITED

SOTAC®

Date: August 11, 2023

To, Listing Compliance Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Bandra East, Mumbai-400051

CIN.: L24230GJ2015PLC085451

Dear Sir,

Sub: Outcome of board meeting held on today i.e. on, August 11, 2023, in terms of second proviso to Regulation 30(6) Of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: Sotac Pharmaceuticals Limited (SYMBOL/ISIN: SOTAC/INE002D01012)

In reference to captioned subject, we hereby inform you that the Board of Directors of the Company, in their Board Meeting held on today, i.e. on Friday, August 11, 2023, at the Registered Office of the Company situated at Plot No. PF-21, Nr. Acme Pharma, Opp. Teva Pharma Sanand GIDC-II, Sanand Ahmedabad-382110, which was commenced at 04:15 P.M. and concluded at 05:15 P.M., to have;

- 1. Considered, approved and taken on record the Unaudited Standalone and Consolidated financial result of the Company for the quarter ended on June 30, 2023.
- 2. Approved the Limited Review Report issued by Statutory Auditors of the Company for the Quarter ended on June 30, 2023.
- 3. Approved Draft Directors report of the company for the financial year 2022-23.
- 4. Decided to call the 8th Annual General Meeting of the Company on Monday, September 11, 2023, at 04:00 P.M. (IST) through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") in compliance with the applicable circulars of Ministry of Corporate Affairs (MCA).

The copy of Notice of 8th Annual General Meeting and Annual Report for the financial year 2022-23 will be submitted to exchange as soon as the same be dispatched to the Shareholders of the Company through e-mail registered with Company/Depositories.

- 5. Approved Schedule of Annual General Meeting w.r.t cutoff date for remote e-voting, remote e-voting start date and end date.
- 6. Appointment of National Securities Depository Limited (NSDL) as Remote E-Voting Agency for resolutions proposed to be passed at Annual General Meeting.
- 7. Approved Appointment of M/s. SCS and CO LLP, Practicing Company Secretary as Scrutinizer for E-Voting Process for AGM.
- 8. Approved Appointment of M/s. Suthar Haresh & Associates, Cost Accountants, as Cost Auditors for the financial year 2023-24. (*Brief Profile of Cost Auditors is enclosed herewith as Annexure I.*)

(Formerly known as, Sotac Pharmaceuticals Private Limited) Registered Office : Plot No. PF/21, Nr. Acme Pharma, Opp. Teva Pharma, Sanand GIDC - II, Sanand, Ahmedabad – 382110, Gujarat (INDIA) CIN.: L24230GJ2015PLC085451 SOTAC

9. Pursuant to the recommendation of the Audit Committee, the Board of Directors of the company has considered and approved the appointment of M/s. Keyur Shah & Co., Chartered Accountants (FRN: 141173W), Ahmedabad as Statutory Auditors of the Company for a First term of Four consecutive years commencing from the conclusion of the 8th Annual General meeting to be held on September 11, 2023 till the conclusion of the 12th AGM of the Company.

The details required under SEBI (LODR) Regulation, 2015 read with Schedule III of The SEBI (LODR) Regulations, 2015 and in terms of SEBI Circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 attached as per Annexure II.

10. On recommendation of Nomination & Remuneration Committee, appointed Ms. Niyati Dipesh Parikh (Membership No. F12289) as Company Secretary & Compliance Officer of the Company w.e.f. August 11, 2023.

The details as required under Regulation 30 read with Schedule III of The SEBI (LODR) Regulations,2015 and in terms of SEBI Circular no. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 is given in the enclosed Annexure III.

11. Considered and approved all other business as per agenda circulated.

Kindly take the same on your record and oblige us.

Thanking you.

Yours faithfully, For, Sotac Pharmaceuticals Limited

Sharadkumar Dashrathbhai Patel Chairman and Managing Director DIN: 07252252

Place: Ahmedabad

(Formerly known as, Sotac Pharmaceuticals Private Limited) Registered Office : Plot No. PF/21, Nr. Acme Pharma, Opp. Teva Pharma, Sanand GIDC - II, Sanand, Ahmedabad – 382110, Gujarat (INDIA) CIN.: L24230GJ2015PLC085451



Annexure I

Details as required under Regulation 30 read with Schedule III of The SEBI (LODR) Regulations, 2015 and in terms of SEBI Circular no. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023

Appointment of Cost Auditors:

| Sr. No. | Details of the event that need to be provided | Information of Such events |
|---------|---|---|
| 1. | Name of the Cost Auditor | M/s. Suthar Haresh & Associates, Cost Accountants (FRN: 002124). |
| 2. | Reason for change viz. appointment, resignation, removal, death or otherwise; | Appointment as Cost Auditors of the Company. |
| 3. | Date of appointment/ cessation & term of appointment | August 11, 2023 For Conducting Cost Audit of the Company for the Financial year 2023-24. |
| 4. | Brief Profile; | Suthar Haresh & Associates, Cost Accountants, having its offices at Ashram Road, Ahmedabad, is providing its highly professional services in the areas of Cost Audit, Cost Compliance, Indirect Taxation, Financial and Legal Consulting. The core management of the firm includes CMA Haresh Suthar as Proprietor. They have a team of highly qualified professionals having rich experience of more than five years in providing Cost Audit & Compliance, Product Costing and other required fields. They provides Services of; Statutory Cost Accountant Services: Such as-Internal audit (general operations or production specific), Preparation and guidance for cost records required under law etc. Cost Consultancy Services: Such as Variance Analysis, Pricing Decisions, Asset Efficiency, Replacement Analysis, Product Mix - Review and Ascertain Best Product Mix, Designing XLS Template for Price Quotation etc. Other Professional Services: Such as Budgeting and Budgetary Controls with special focus on profit management, Stock / Asset Audit – Physical Verification, Develop tailor-made MIS for Best Decision Making etc. |
| 5. | Disclosure of relationships between directors (in case of appointment of a director) | Not Applicable |
| 6. | Information as required pursuant to NSE Circular with Ref No. NSE/CML/2018/24 dated June 20, 2018 | - |

Contact No.: 99135 62852, 87994 83159, 99250 45971 www.sotacpharma.com Sotacpharma@gmail.com

(Formerly known as, Sotac Pharmaceuticals Private Limited) Registered Office : Plot No. PF/21, Nr. Acme Pharma, Opp. Teva Pharma, Sanand GIDC - II, Sanand, Ahmedabad – 382110, Gujarat (INDIA) CIN.: L24230GJ2015PLC085451



Annexure II

Details as required under Regulation 30 read with Schedule III of The SEBI (LODR) Regulations, 2015 and in terms of SEBI Circular no. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023

Appointment of Statutory Auditors:

| Sr. No. | Particulars | Details |
|---------|--|--|
| 1. | Name of the Company | Sotac Pharmaceuticals Limited |
| 2. | Name of Auditor | M/s. Keyur Shah & Co., Chartered Accountants (FRN: 141173W), Ahmedabad. |
| 3. | Reason for Change viz., appointment, resignation, removal, death or otherwise | Appointment as Statutory Auditors at 8 th Annual General meeting to be held on September 11, 2023. |
| 4. | Date of appointment/ re appointment / cessation (as applicable) & term of appointment /re-appointment | Appointment of M/s. Keyur Shah & Co., Chartered Accountants (FRN: 141173W), Ahmedabad as Statutory Auditors of the Company for a First term of Four consecutive years commencing from the conclusion of the 08th Annual General meeting to be held on September 11, 2023 till the conclusion of the 12th AGM of the Company. Which shall be subject to approval of Shareholder at the ensuing Annual General Meeting of the Company. |
| 5. | Brief profile | Keyur Shah & Co. is a professionally managed Chartered Accountants Firm having its offices in Ahmedabad, Gujarat. The firm was founded by Mr. Keyur Shah, he brings a wealth of experience spanning over 12 years in various domains such as capital markets, project funding, direct tax, business advisory, tax advisory, and business valuations. With his expertise, he has become an FAFD (Forensic Audit and Fraud Detection) certified professional. Keyur Shah & Co. has a dedicated professionals collaborated to provide Project Finance, Audit, Consulting, Financial & Corporate Advisory, Fund Raising, Capital Market, Wealth Management, Tax, Legal and Related Services to Clients. |
| | | An One Stop Single Window Advisory Firm offering Integrated Business, Legal and Financial Solutions to varied sections of society including SMEs and Large Corporate Enterprises. The firm is committed to providing high-quality, ethical services to its clients. |
| 6. | Disclosure of relationships between directors (in case of appointment of a director) | Not Applicable |
| 7. | Information as required pursuant to NSE Circular with Ref No. NSE/CML/2018/24 dated June 20, 2018 | - |

(Formerly known as, Sotac Pharmaceuticals Private Limited) Registered Office : Plot No. PF/21, Nr. Acme Pharma, Opp. Teva Pharma, Sanand GIDC - II, Sanand, Ahmedabad – 382110, Gujarat (INDIA) CIN.: L24230GJ2015PLC085451



Annexure III

Details as required under Regulation 30 read with Schedule III of The SEBI (LODR) Regulations, 2015 and in terms of SEBI Circular no. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023

Name of Key Managerial Personnel: Ms. Niyati Dipesh Parikh

| Sr.No. | Particulars | Details |
|--------|---|--|
| 1. | Reason for change viz. appointment, resignation, removal, death or otherwise | Appointment |
| 2. | Name and Date of Birth | Ms. Niyati Dipesh Parikh |
| 3. | Date of appointment and Term of appointment | Date of Appointment: August 11, 2023. Term of Appointment: Appointed as Company Secretary & Compliance Officer of the Company. |
| 4. | Education Qualification | Company Secretary (C.S.), B.com, LLB |
| 5. | Brief Profile | Ms. Niyati Parikh is a Fellow Member of the Institute of Company Secretaries of India with a Bachelor Degree in Commerce and Bachelor Degree in Law. She has behind her a work experience of 6 years as a Company Secretary and Compliance officer. Her varied areas of knowledge includes Corporate laws, Secretarial Management guidance, Due Diligence, Compliance Audit, Corporate Governance Audit, Merger – Acquisition, FEMA and other Economic Laws. |
| 6. | Disclosure of relationships between directors (In case of appointment of Director) | Not Applicable |

(Formerly known as, Sotac Pharmaceuticals Private Limited) Registered Office : Plot No. PF/21, Nr. Acme Pharma, Opp. Teva Pharma, Sanand GIDC - II, Sanand, Ahmedabad – 382110, Gujarat (INDIA) CIN.: L24230GJ2015PLC085451

SOTAC PHARMACEUTICALS LIMITED

SOTAC®

Date: August 11, 2023

To, Listing Compliance Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Bandra East, Mumbai-400051

Dear Sir,

Sub: Submission of Unaudited Standalone and Consolidated Financial Result of the Company for the quarter ended on June 30, 2023 along with Limited Review Report.

Ref: Sotac Pharmaceuticals Limited (SYMBOL/ISIN: SOTAC/INE002D01012)

In reference to captioned subject and pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter ended on June 30, 2023 along with Limited Review Report issued by Statutory Auditors on the Unaudited Standalone and Consolidated Financial Results for the Quarter ended on June 30, 2023.

Kindly take the same on your record and disseminate the same on your website and oblige us.

Thanking You,

Yours faithfully,

For, Sotac Pharmaceuticals Limited

Sharadkumar Dashrathbhai Patel Chairman and Managing Director DIN: 07252252

Place: Ahmedabad



CA Keyur Shah FCA, B.Com, ISA, FAFP Certified

Limited Review Report on unaudited standalone financial results of Sotac Pharmaceutical Limited for the Quarter ended 30 June 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,

The Board of Directors Of, Sotac Pharmaceutical Limited (Formerly Known As Sotac Pharmaceutical Private Limited)

We have reviewed the accompanying the statement of unaudited Standalone financial results ("the financial statement") of **Sotac Pharmaceutical Limited** ("the Company") for the Quarter ended on June 30, 2023. The Financial Statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down as per accounting standard prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information performed by the independent Auditor of the Entity", issued by the institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primary to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited Standalone financial results, prepared in accordance with applicable standards and other recognized accounting practices and policies has not disclosed the information require to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Keyur Shah & Co. Chartered Accountants F.R. No. 141173W

Date: - 11th August, 2023 Place: - Ahmedabad

303, Shitiratna, B/s. Radisson Blu Hotel, Nr. Panchvati Circle, Ambawadi, Ahmedabad-380006. Gujarat, INDIA. Ph. : +91 79 48999595, M. : +91 999 8484 564 • Website : www.keyurshahca.com E-mail : keyur@keyurshahca.com, ca.keyurshah2015@gmail.com

| | STANDALONE STATEME | | | | GIDC-II, Ahmedabad-3 RTER ENDED JUNE 30, | | |
|--|--|--|--|--|---|---|--|
| | | | | | | NR in Lakhs unless other | wise Specified) |
| - | | | | | Quarter ended | INK III LAKIIS UIIIESS OUIEI | Year ended |
| Sr no. | Particulars | | | 30.06.2023 | 31.03.2023 | 30.06.2022 | 31.03.2023 |
| | | | | Unaudited | Audited | Unaudited | Audited * |
| 1) 11) | REVENUE FROM OPERATIONS OTHER INCOME | | | 1891.05 23.15 | 1317.82 12.53 | 1504.72 6.76 | 5798.2 24.3 |
| III) | TOTAL REVENUE (I + II) | | | 1914.20 | 1330.35 | 1511.48 | 5822.5 |
| 10.575 | Construction and a second of the second s | | | 1914.20 | 1330.35 | 1511.46 | 5622.5 |
| IV) | EXPENSES | | | | | | |
| | Cost of Material Consumed Purchase of Stock-in-Trade | | | 1199.35 7.73 | 1090.51 18.15 | 1010.69 7.83 | 4272.3 52.6 |
| | Changes in Inventories of Finished Goods/ Work-In-Progre | ess/ Stock in Trade | | 66.36 | (300.09) | 8.01 | (318.3 |
| d) | Employee Benefit Expenses | | | 72.27 | 73.49 | 63.53 | 292.6 |
| | Finance Costs | | | 34.20 | 30.55 | 17.23 | 86.1 |
| | Depreciation and Amortisation Expense | | | 46.27 | 45.46 197.62 | 33.60 122.04 | 162.5 |
| B) | Other Expenses | | | 319.38 | | | |
| | TOTAL EXPENSES (IV) | | | 1745.56 | 1155.69 | 1262.93 | 5226.1 |
| V) | PROFIT/(LOSS) BEFORE EXCEPTIONAL & EXTRAORDINAR | Y ITEMS & TAX (III - | · IV) | 168.64 | 174.66 | 248.55 | 596.4 |
| VI) | Exceptional/Prior Period Items | | | - | e 1 | - | |
| VII) | PROFIT BEFORE EXTRAORDINARY ITEMS & TAX (V-VI) | | | 168.64 | 174.66 | 248.55 | 596.4 |
| | | | - | 100.04 | 174.00 | 240.55 | |
| VIII) | Extraordinary Items | | | - | | 1 | 201 |
| IX) | PROFIT BEFORE TAX (VII-VIII) | | | 168.64 | 174.66 | 248.55 | 596.4 |
| X) | TAX EXPENSE | | | | | | |
| | Current Tax | | | 45.63 | 48.87 | 70.08 | 168 3 |
| | Deferred Tax | | | 2.48 | 2.41 | (7.11) | (21.49 |
| 077.6 | | | | | | 10.000 | 0.52550.73 |
| | TOTAL TAX EXPENSE (X) | | | 48.11 | 51.28 | 62.97 | 146.9 |
| XI) | PROFIT / (LOSS) FOR THE PERIOD/YEAR (IX-X) | | | 120.53 | 123.38 | 185.58 | 449.5 |
| XII) | Paidup Equity Share Capital (Face value Rs 10 each) | | | 1105.00 | 805.00 | 230.00 | 805.0 |
| AII) | r biddp Eddity Share capital (rate value ha 10 coerry | | | 1105.00 | 000.00 | 230.00 | 005.0 |
| KIII) | Reserve & Surplus (Excluding Revaluation Reserve) | | | | | | 346.9 |
| | | | | | | | |
| XIII) | EARNINGS PER EQUITY SHARE-BASIC/DILUTED | | | | 1 | | |
| | EARNINGS PER EQUITY SHARE-BASIC/DILUTED Basic /Diluted earnings per share (In INR) | | | 1.12 | 1.53 | 8.07 | 5.5 |
| - 19 | | | | 1.12 | 1.53 | 8.07 | 5.5 |
| otas: | Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended) | fance with the Accou | nting Standards I | | | | |
| otas: [] The | Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended) | | | | | | |
| otas:] The | Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended) | practices and policies, | , as applicable | Prescribed urder Sec | tion 133 of the Compani | es Act,2013 read with Ru | ile 7 of the Compar |
| otas:] The Accou | Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended) standalone unaudited financial results are prepared in accord nts) Rules, 2014 (as amended) and other recegnised accounting above standalone unaudited financial results for the quarter e | practices and policies, inded June 30, 2023 h | , as applicable nave been prepar | Prescribed urder Sec ed by the Company | tion 133 of the Compani | es Act,2013 read with Ru lation 33 of SEBI (Listing (| ule 7 of the Company |
| otas:] The Accou !] The equire | Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended) | practices and policies, ended June 30, 2023 h d recommended by th | , as applicable have been prepar he Audit Committ | Prescribed urder Sec ed by the Company ee of the Board and | tion 133 of the Compani in accordance with Regu thereafter were approve | es Act,2013 read with Ru lation 33 of SEBI (Listing (| ule 7 of the Compan bligation & Disclose |
| otas: J The ccou J The equire their | Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended) standalone unaudited financial results are prepared in accord nts) Rules, 2014 (as amended) and other recegnised accounting above standalone unaudited financial results for the quarter e ements) Regulations 2015 (as amended) and were reviewed and meeting held on August 11,2023. A limited review of the above | practices and policies, inded June 30, 2023 h d recommended by th results has been carri | , as applicable have been prepar he Audit Committ hed out by the sta | Prescribed urder Sec ed by the Company ee of the Board and tutory auditors of th | tion 133 of the Compani in accordance with Regu thereafter were approve e company | es Act,2013 read with Ru lation 33 of SEBI (Listing (d and taken on record by | ile 7 of the Compan Dbligation & Disclosi the Board of Direct |
| otas:] The ccou] The equire their] The | Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended) estandalone unaudited financial results are prepared in accord nts) Rules, 2014 (as amended) and other recegnised accounting above standalone unaudited financial results for the quarter e ements) Regulations 2015 (as amended) and were reviewed and meeting held on August 11,2023 A limited review of the above figures for the quarter ended 31 March 2023 are the Balancing | practices and policies, inded June 30, 2023 h d recommended by th results has been carri | , as applicable have been prepar he Audit Committ hed out by the sta | Prescribed urder Sec ed by the Company ee of the Board and tutory auditors of th | tion 133 of the Compani in accordance with Regu thereafter were approve e company | es Act,2013 read with Ru lation 33 of SEBI (Listing (d and taken on record by | ile 7 of the Compar J Dbligation & Disclos the Board of Direct |
| otas:] The ccou] The equire their The | Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended) estandalone unaudited financial results are prepared in accord nts) Rules, 2014 (as amended) and other recognised accounting above standalone unaudited financial results for the quarter e ements) Regulations 2015 (as amended) and were reviewed and meeting held on August 11,2023 A limited review of the above figures for the quarter ended 31 March 2023 are the Balancing ber 2022 which are sujbect to limited review. | practices and policies, ended June 30, 2023 h d recommended by th results has been carri figures between the a | , as applicable lave been prepar le Audit Committ led out by the sta audited figures in | Prescribed urder Sec ed by the Company ee of the Board and tutory auditors of th respect of full finan | tion 133 of the Compani in accordance with Regu thereafter were approve e company | es Act,2013 read with Ru lation 33 of SEBI (Listing (d and taken on record by | ile 7 of the Compan Dbligation & Disclosi the Board of Direct |
| otas:] The Accou] The equire their [] The ecem | Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended) estandalone unaudited financial results are prepared in accord nts) Rules, 2014 (as amended) and other recegnised accounting above standalone unaudited financial results for the quarter e ements) Regulations 2015 (as amended) and were reviewed and meeting held on August 11,2023 A limited review of the above figures for the quarter ended 31 March 2023 are the Balancing | practices and policies, ended June 30, 2023 h d recommended by th results has been carri figures between the a | , as applicable lave been prepar le Audit Committ led out by the sta audited figures in | Prescribed urder Sec ed by the Company ee of the Board and tutory auditors of th respect of full finan | tion 133 of the Compani in accordance with Regu thereafter were approve e company | es Act,2013 read with Ru lation 33 of SEBI (Listing (d and taken on record by | ile 7 of the Compan Dbligation & Disclosi the Board of Direct |
| otas:) The equire their) The ecem) The) The | Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended) estandalone unaudited financial results are prepared in accord nts) Rules, 2014 (as amended) and other recognised accounting above standalone unaudited financial results for the quarter e ements) Regulations 2015 (as amended) and were reviewed and meeting held on August 11,2023 A limited review of the above figures for the quarter ended 31 March 2023 are the Balancing ber 2022 which are sujbect to limited review. figures of the previous period have been re-grouped / rearrange Company has Voluntarily adopted the quarterly standalone una | practices and policies, ended June 30, 2023 h d recommended by th results has been carri figures between the a ed and / or recasted w sudited financial result | , as applicable have been prepar- ne Audit Committ ied out by the sta audited figures in wherever consider ts for the quarter | Prescribed urder Sec ed by the Company ee of the Board and tutory auditors of th respect of full finan ed necessary. ended 30th June 202 | tion 133 of the Compani in accordance with Regu thereafter were approve e company cial year and the year-to- 23. | es Act,2013 read with Ru lation 33 of SEBI (Listing (d and taken on record by date figures up to the thir | ile 7 of the Compan Dbligation & Discloss the Board of Direct rd quarter ended on |
| lotas:] The Accou] The equire their their] The] The | Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended) estandalone unaudited financial results are prepared in accord nts) Rules, 2014 (as amended) and other recegnised accounting above standalone unaudited financial results for the quarter e ements) Regulations 2015 (as amended) and were reviewed and meeting held on August 11,2023. A limited review of the above figures for the quarter ended 31 March 2023 are the Balancing ber 2022 which are subect to limited review. figures of the previous period have been re-grouped / rearrange | practices and policies, ended June 30, 2023 h d recommended by th results has been carri figures between the a ed and / or recasted w sudited financial result | , as applicable have been prepar- ne Audit Committ ied out by the sta audited figures in wherever consider ts for the quarter | Prescribed urder Sec ed by the Company ee of the Board and tutory auditors of th respect of full finan ed necessary. ended 30th June 202 | tion 133 of the Compani in accordance with Regu thereafter were approve e company cial year and the year-to- 23. | es Act,2013 read with Ru lation 33 of SEBI (Listing (d and taken on record by date figures up to the thir | ile 7 of the Compan Dbligation & Discloss the Board of Direct rd quarter ended on |
| lotes: 1] The Accou 1] The equire 1] The 1] The 1] The 1] The 1] The 1] Con | Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended) e standalone unaudited financial results are prepared in accord nts) Rules, 2014 (as amended) and other recognised accounting a above standalone unaudited financial results for the quarter e ements) Regulations 2015 (as amended) and were reviewed and meeting held on August 11,2023. A limited review of the above figures for the quarter ended 31 March 2023 are the Balancing ber 2022 which are sujbect to limited review. figures of the previous period have been re-grouped / rearrange Company has Voluntarily adopted the quarterly standalone una npany is mainly engaged in manufacturing of of a wide range o | practices and policies, ended June 30, 2023 h d recommended by th results has been carri figures between the a ed and / or recasted w sudited financial result of pharmaceutical proc | , as applicable nave been prepar be Audit Committ ied out by the sta audited figures in wherever consider ts for the quarter ducts such as Noi | Prescribed urder Sec ed by the Company ee of the Board and tutory auditors of th respect of full finan ed necessary. ended 30th June 20: n Beta-Lactam (gene | tion 133 of the Compani in accordance with Regu thereafter were approve e company cial year and the year-to- 23. rral) tablets, Non Beta-Lar | es Act,2013 read with Ru lation 33 of SEBI (Listing (d and taken on record by date figures up to the thin ctam (general) capsules, f | Dbligation & Disclose the Board of Directe rd quarter ended on |
| lotes:) The Accou) The equiri- i their) The) The (The) The) The) The (The) The) The (The) The) The (The) The (The (The) The (The (The (The (The) The (The (The (The (The (The (The (The | Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended) estandalone unaudited financial results are prepared in accord nts) Rules, 2014 (as amended) and other recegnised accounting above standalone unaudited financial results for the quarter e ements) Regulations 2015 (as amended) and were reviewed and meeting held on August 11,2023 A limited review of the above figures for the quarter ended 31 March 2023 are the Balancing ber 2022 which are sujbect to limited review. figures of the previous period have been re-grouped / rearrange Company has Voluntarily adopted the quarterly standalone una | practices and policies, inded June 30, 2023 h d recommended by th results has been carri figures between the a ed and / or recasted w nudited financial result of pharmaceutical proc is operating under sin | , as applicable have been prepar se Audit Committ led out by the sta audited figures in wherever consider ts for the quarter ducts such as Nor logie segment hen | Prescribed urder Sec ed by the Company ee of the Board and tutory auditors of th respect of full finan ed necessary. ended 30th June 20: n Beta-Lactam (gene ce segment reportin | tion 133 of the Compani in accordance with Regu thereafter were approve e company cial year and the year-to- 23. rral) tablets, Non Beta-Lang is not applicable to Cor | es Act,2013 read with Ru lation 33 of SEBI (Listing (d and taken on record by date figures up to the thin ctam (general) capsules, f npany. | ule 7 of the Compan Dbligation & Discloss the Board of Direct rd quarter ended on Non Beta-lactam Syr |
| lotes:) The Accou) The equiri- i their) The) The (The) The) The) The (The) The) The (The) The) The (The) The (The (The) The (The (The (The (The) The (The (The (The (The (The (The (The | Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended) estandalone unaudited financial results are prepared in accord nts) Rules, 2014 (as amended) and other recegnised accounting above standalone unaudited financial results for the quarter e ements) Regulations 2015 (as amended) and were reviewed and meeting held on August 11,2023. A limited review of the above figures for the quarter ended 31 March 2023 are the Balancing ber 2022 which are sujbect to limited review. figures of the previous period have been re-grouped / rearrange Company has Voluntarily adopted the quarterly standalone una npany is mainly engaged in manufacturing of of a wide range o ternal preparations looking into the nature of business company | practices and policies, inded June 30, 2023 h d recommended by th results has been carri figures between the a ed and / or recasted w nudited financial result of pharmaceutical proc is operating under sin | , as applicable have been prepar se Audit Committ led out by the sta audited figures in wherever consider ts for the quarter ducts such as Nor logie segment hen | Prescribed urder Sec ed by the Company ee of the Board and tutory auditors of th respect of full finan ed necessary. ended 30th June 20: n Beta-Lactam (gene ce segment reportin | tion 133 of the Compani in accordance with Regu thereafter were approve e company cial year and the year-to- 23. rral) tablets, Non Beta-Lang is not applicable to Cor | es Act,2013 read with Ru lation 33 of SEBI (Listing (d and taken on record by date figures up to the thin ctam (general) capsules, f npany. | ule 7 of the Compan Dbligation & Discloss the Board of Direct rd quarter ended on Non Beta-lactam Syr |
| otes:] The equin their] The ecem] The] The] Con id ext]The | Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended) estandalone unaudited financial results are prepared in accord nts) Rules, 2014 (as amended) and other recegnised accounting above standalone unaudited financial results for the quarter e ements) Regulations 2015 (as amended) and were reviewed and meeting held on August 11,2023. A limited review of the above figures for the quarter ended 31 March 2023 are the Balancing ber 2022 which are sujbect to limited review. figures of the previous period have been re-grouped / rearrange Company has Voluntarily adopted the quarterly standalone una npany is mainly engaged in manufacturing of of a wide range o ternal preparations looking into the nature of business company | practices and policies, ended June 30, 2023 h d recommended by th results has been carri figures between the a ed and / or recasted w sudited financial result of pharmaceutical proor is operating under sin equity shares of face w | , as applicable nave been prepar ne Audit Committ ied out by the sta audited figures in wherever consider ts for the quarter ducts such as Nor ngle segment hen value of Rs. 10/-1 | Prescribed urder Sec ed by the Company ee of the Board and tutory auditors of th respect of full finan ed necessary. ended 30th June 20: n Beta-Lactam (gene ce segment reportir each fully paid up for | tion 133 of the Compani in accordance with Regu thereafter were approve e company cial year and the year-to- 23. rral) tablets, Non Beta-Lan g is not applicable to Cor r cash at a price of Rs. 11 | es Act,2013 read with Ru lation 33 of SEBI (Listing (d and taken on record by date figures up to the thir ctam (general) capsules, f npany. 1/- per equity share(inclu | ile 7 of the Compar Obligation & Disclos the Board of Direct rd quarter ended on Non Beta-lactam Syl ding share premium |
| otas:) The cccou) The equiro their) The ccem) The Con d ext (The 101 | Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended) e standalone unaudited financial results are prepared in accord nts) Rules, 2014 (as amended) and other recegnised accounting above standalone unaudited financial results for the quarter e ements) Regulations 2015 (as amended) and were reviewed and meeting held on August 11,2023 A limited review of the above figures for the quarter ended 31 March 2023 are the Balancing ber 2022 which are sujbect to limited review. figures of the previous period have been re-grouped / rearrange Company has Voluntarily adopted the quarterly standalone una npany is mainly engaged in manufacturing of of a wide range o ternal preparations looking into the nature of business company company had made an initial public offering (IPO) of 30,00,000 of | practices and policies, ended June 30, 2023 h d recommended by th results has been carri figures between the a ed and / or recasted w sudited financial result of pharmaceutical proc is operating under sin equity shares of face w nentioned equity shar | , as applicable have been prepar he Audit Committ ied out by the sta audited figures in wherever consider ts for the quarter ducts such as Nor high segment hen value of Rs. 10/- i es of the compar | Prescribed urder Sec ed by the Company ee of the Board and tutory auditors of th respect of full finan ed necessary. ended 30th June 20: n Beta-Lactam (gene ce segment reportir each fully paid up for | tion 133 of the Compani in accordance with Regu thereafter were approve e company cial year and the year-to- 23. rral) tablets, Non Beta-Lan g is not applicable to Cor r cash at a price of Rs. 11 | es Act,2013 read with Ru lation 33 of SEBI (Listing (d and taken on record by date figures up to the thir ctam (general) capsules, f npany. 1/- per equity share(inclu | ile 7 of the Compar Obligation & Disclos the Board of Direct rd quarter ended on Non Beta-lactam Syl ding share premium |
| otes:) The equire their) The ecem) The) The 1 The 1 The 1 101 1 | Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended) estandalone unaudited financial results are prepared in accord nts) Rules, 2014 (as amended) and other recegnised accounting above standalone unaudited financial results for the quarter e ements) Regulations 2015 (as amended) and were reviewed and meeting held on August 11,2023. A limited review of the above figures for the quarter ended 31 March 2023 are the Balancing ber 2022 which are sujbect to limited review. figures of the previous period have been re-grouped / rearrange Company has Voluntarily adopted the quarterly standalone una npany is mainly engaged in manufacturing of of a wide range o ternal preparations looking into the nature of business company company had made an initial public offering (IPO) of 30,00,000 or per equity share) aggregating to Rs.3330.00/- Lakhs. The aforem The Status of investor's complaints during the year ended on Jun | practices and policies, ended June 30, 2023 h d recommended by th results has been carri figures between the a ed and / or recasted w sudited financial result of pharmaceutical proc is operating under sin equity shares of face w nentioned equity shar | , as applicable have been prepar he Audit Committ ied out by the sta audited figures in wherever consider ts for the quarter ducts such as Nor high segment hen value of Rs. 10/- i es of the compar | Prescribed urder Sec ed by the Company ee of the Board and tutory auditors of th respect of full finan ed necessary. ended 30th June 20: n Beta-Lactam (gene ce segment reportin each fully paid up for ny alloted as on 10th | tion 133 of the Compani in accordance with Regu thereafter were approve e company cial year and the year-to- 23. rral) tablets, Non Beta-Lan g is not applicable to Cor r cash at a price of Rs. 11 | es Act,2013 read with Ru lation 33 of SEBI (Listing (d and taken on record by date figures up to the thir ctam (general) capsules, f npany. 1/- per equity share(inclu | ile 7 of the Compar Obligation & Disclos the Board of Direct rd quarter ended on Non Beta-lactam Sy ding share premium |
| their The ccou The ccem The Con The Con d ext The 101 | Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended) estandalone unaudited financial results are prepared in accord nts) Rules, 2014 (as amended) and other recegnised accounting above standalone unaudited financial results for the quarter e ements) Regulations 2015 (as amended) and were reviewed and meeting held on August 11,2023 A limited review of the above figures for the quarter ended 31 March 2023 are the Balancing ber 2022 which are sujbect to limited review. figures of the previous period have been re-grouped / rearrange Company has Voluntarily adopted the quarterly standalone una npany is mainly engaged in manufacturing of of a wide range o ternal preparations looking into the nature of business company company had made an initial public offering (IPO) of 30,00,000 of per equity share) aggregating to Rs.3330.00/- Lakhs. The aforem The Status of investor's complaints during the year ended on Jun Complaints pending at the beginning of the period | practices and policies, ended June 30, 2023 h d recommended by th results has been carri figures between the a ed and / or recasted w sudited financial result of pharmaceutical proc is operating under sin equity shares of face w nentioned equity shar | , as applicable have been prepar he Audit Committ ied out by the sta audited figures in wherever consider ts for the quarter ducts such as Nor high segment hen value of Rs. 10/- i es of the compar | Prescribed urder Sec ed by the Company ee of the Board and tutory auditors of th respect of full finan ed necessary. ended 30th June 20: n Beta-Lactam (gene ce segment reportin each fully paid up for hy alloted as on 10th Nill | tion 133 of the Compani in accordance with Regu thereafter were approve e company cial year and the year-to- 23. rral) tablets, Non Beta-Lan g is not applicable to Cor r cash at a price of Rs. 11 | es Act,2013 read with Ru lation 33 of SEBI (Listing (d and taken on record by date figures up to the thir ctam (general) capsules, f npany. 1/- per equity share(inclu | ile 7 of the Compar Obligation & Disclos the Board of Direct rd quarter ended on Non Beta-lactam Sy ding share premium |
| otes: The ccou The equiriter their The The Con d ext The 101 | Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended) estandalone unaudited financial results are prepared in accord nts) Rules, 2014 (as amended) and other recegnised accounting above standalone unaudited financial results for the quarter e ements) Regulations 2015 (as amended) and were reviewed and meeting held on August 11,2023. A limited review of the above figures for the quarter ended 31 March 2023 are the Balancing ber 2022 which are sujbect to limited review. figures of the previous period have been re-grouped / rearrange Company has Voluntarily adopted the quarterly standalone una npany is mainly engaged in manufacturing of of a wide range o ternal preparations looking into the nature of business company company had made an initial public offering (IPO) of 30,00,000 or per equity share) aggregating to Rs.3330.00/- Lakhs. The aforem The Status of investor's complaints during the year ended on Jun | practices and policies, ended June 30, 2023 h d recommended by th results has been carri figures between the a ed and / or recasted w sudited financial result of pharmaceutical proc is operating under sin equity shares of face w nentioned equity shar | , as applicable have been prepar he Audit Committ ied out by the sta audited figures in wherever consider ts for the quarter ducts such as Nor high segment hen value of Rs. 10/- i es of the compar | Prescribed urder Sec ed by the Company ee of the Board and tutory auditors of th respect of full finan ed necessary. ended 30th June 20: n Beta-Lactam (gene ce segment reportin each fully paid up for ny alloted as on 10th | tion 133 of the Compani in accordance with Regu thereafter were approve e company cial year and the year-to- 23. rral) tablets, Non Beta-Lan g is not applicable to Cor r cash at a price of Rs. 11 | es Act,2013 read with Ru lation 33 of SEBI (Listing (d and taken on record by date figures up to the thir ctam (general) capsules, f npany. 1/- per equity share(inclu | ile 7 of the Compar Obligation & Disclos the Board of Direct rd quarter ended on Non Beta-lactam Syl ding share premium |
| otas:) The ccou) The equire their their) The) The) Con d ext 1 The 1 | Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended) estandalone unaudited financial results are prepared in accord nts) Roles, 2014 (as amended) and other recognised accounting above standalone unaudited financial results for the quarter e ements) Regulations 2015 (as amended) and were reviewed and meeting held on August 11,2023. A limited review of the above figures for the quarter ended 31 March 2023 are the Balancing ber 2022 which are sujbect to limited review. figures of the previous period have been re-grouped / rearrange Company has Voluntarily adopted the quarterly standalone una npany is mainly engaged in manufacturing of of a wide range o ternal preparations looking into the nature of business company company had made an initial public offering (IPO) of 30,00,000 of per equity share) aggregating to Rs.3330.00/- Lakhs. The aforem The Status of investor's complaints during the year ended on Jun Complaints pending at the beginning of the period Complaints received during the period | practices and policies, ended June 30, 2023 h d recommended by th results has been carri figures between the a ed and / or recasted w sudited financial result of pharmaceutical proc is operating under sin equity shares of face w nentioned equity shar | , as applicable have been prepar he Audit Committ ied out by the sta audited figures in wherever consider ts for the quarter ducts such as Nor high segment hen value of Rs. 10/- i es of the compar | Prescribed urder Sec ed by the Company ee of the Board and tutory auditors of th respect of full finan ed necessary. ended 30th June 20: n Beta-Lactam (gene ce segment reportir each fully paid up fo ny alloted as on 10th Nill 1 | tion 133 of the Compani in accordance with Regu thereafter were approve e company cial year and the year-to- 23. rral) tablets, Non Beta-Lan g is not applicable to Cor r cash at a price of Rs. 11 | es Act,2013 read with Ru lation 33 of SEBI (Listing (d and taken on record by date figures up to the thir ctam (general) capsules, f npany. 1/- per equity share(inclu | ile 7 of the Compar Obligation & Disclos the Board of Direct rd quarter ended on Non Beta-lactam Syl ding share premium |
| otas: The ccou The equire their The The Con The 101 | Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended) estandalone unaudited financial results are prepared in accord nts) Rules, 2014 (as amended) and other recegnised accounting above standalone unaudited financial results for the quarter e ements) Regulations 2015 (as amended) and were reviewed and meeting held on August 11,2023 A limited review of the above figures for the quarter ended 31 March 2023 are the Balancing ber 2022 which are sujbect to limited review. figures of the previous period have been re-grouped / rearrange Company has Voluntarily adopted the quarterly standalone una npany is mainly engaged in manufacturing of of a wide range o ternal preparations looking into the nature of business company company had made an initial public offering (IPO) of 30,00,000 of per equity share) aggregating to Rs.3330.00/- Lakhs. The aforem The Status of investor's complaints during the year ended on Jun Complaints pending at the beginning of the period Complaints reseived during the period Complaints during the period Complaints resolved at the end of the period | practices and policies, inded June 30, 2023 h d recommended by th results has been carri figures between the a ed and / or recasted w undited financial result of pharmaceutical proc is operating under sin equity shares of face so nentioned equity shar- ne 30, 2023 as under;- | , as applicable have been prepar he Audit Committ ied out by the sta audited figures in wherever consider ts for the quarter ducts such as Nor high segment hen value of Rs. 10/- r es of the compar | Prescribed urder Sec ed by the Company ee of the Board and tutory auditors of th respect of full finan ed necessary. ended 30th June 20: n Beta-Lactam (gene ce segment reportin each fully paid up for hy alloted as on 10th Nill 1 1 Nill | tion 133 of the Compani in accordance with Regu thereafter were approve e company cial year and the year-to- 23. rral) tablets, Non Beta-Lan g is not applicable to Cor r cash at a price of Rs. 11 | es Act,2013 read with Ru lation 33 of SEBI (Listing (d and taken on record by date figures up to the thir ctam (general) capsules, f npany. 1/- per equity share(inclu | ile 7 of the Compar Obligation & Disclos the Board of Direct rd quarter ended on Non Beta-lactam Syl ding share premium |
| ottas: The ccou The quirt their The Con d ext The 101 | Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended) estandalone unaudited financial results are prepared in accord nts) Rules, 2014 (as amended) and other recegnised accounting above standalone unaudited financial results for the quarter e ements) Regulations 2015 (as amended) and were reviewed and meeting held on August 11,2023. A limited review of the above figures for the quarter ended 31 March 2023 are the Balancing ber 2022 which are sujbect to limited review. figures of the previous period have been re-grouped / rearrange Company has Voluntarily adopted the quarterly standalone una npany is mainly engaged in manufacturing of of a wide range o ternal preparations looking into the nature of business company company had made an initial public offering (IPO) of 30,00,000 or per equity share) aggregating to Rs.3330.00/- Lakhs. The aforem The Status of investor's complaints during the year ended on Jun Complaints pending at the beginning of the period Complaints disposed during the period Complaints resolved at the end of the period. The Proceeds from the IPO before Net off Issue related expenses | practices and policies, inded June 30, 2023 h d recommended by th results has been carri figures between the a ed and / or recasted w uudited financial result of pharmaceutical proc is operating under sin equity shares of face w nentioned equity shar ne 30, 2023 as under; s is RS. 3,330.00 Lakhs | , as applicable have been prepar se Audit Committ led out by the sta audited figures in wherever consider ts for the quarter ducts such as Nor hgle segment hen value of Rs. 10/- i es of the compar | Prescribed urder Sec ed by the Company ee of the Board and tutory auditors of th respect of full finan ed necessary. ended 30th June 20: n Beta-Lactam (gene ce segment reportin each fully paid up for hy alloted as on 10th Nill 1 1 Nill he are as follows: | tion 133 of the Compani in accordance with Regu thereafter were approve e company cial year and the year-to- 23. rral) tablets, Non Beta-Lan g is not applicable to Cor r cash at a price of Rs. 11 | es Act,2013 read with Ru lation 33 of SEBI (Listing (d and taken on record by date figures up to the thir ctam (general) capsules, f npany. 1/- per equity share(inclu | ile 7 of the Compar Obligation & Disclos the Board of Direct rd quarter ended on Non Beta-lactam Syl ding share premium |
| otes:) The ccou) The equire their) The cem) The 1 On d ext 101 | Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended) estandalone unaudited financial results are prepared in accord nts) Rules, 2014 (as amended) and other recognised accounting above standalone unaudited financial results for the quarter e ements) Regulations 2015 (as amended) and were reviewed and meeting held on August 11,2023 A limited review of the above figures for the quarter ended 31 March 2023 are the Balancing ber 2022 which are sujbect to limited review. figures of the previous period have been re-grouped / rearrange Company has Voluntarily adopted the quarterly standalone una npany is mainly engaged in manufacturing of of a wide range o ternal preparations looking into the nature of business company company had made an initial public offering (IPO) of 30,00,000 of per equity share) aggregating to Rs.3330,00/- Lakhs. The aforem The Status of investor's complaints during the year ended on Jun Complaints pending at the beginning of the period Complaints received during the period Complaints received at the end of the period Complaints resolved at the end of the period | practices and policies, ended June 30, 2023 h d recommended by th results has been carri figures between the a ed and / or recasted w nudited financial result of pharmaceutical proc is operating under sin equity shares of face w nentioned equity shar the 30 ,2023 as under:- | , as applicable have been prepar he Audit Committ fed out by the sta audited figures in wherever consider ts for the quarter ducts such as Nor high segment hen value of Rs. 10/- i es of the compar | Prescribed urder Sec ed by the Company ee of the Board and tutory auditors of th respect of full finan ed necessary. ended 30th June 20: n Beta-Lactam (gene ce segment reportir each fully paid up fo ny alloted as on 10th Nill 1 1 Nill he are as follows: Pending to | tion 133 of the Compani in accordance with Regu thereafter were approve e company cial year and the year-to- 23. rral) tablets, Non Beta-Lan g is not applicable to Cor r cash at a price of Rs. 11 | es Act,2013 read with Ru lation 33 of SEBI (Listing (d and taken on record by date figures up to the thir ctam (general) capsules, f npany. 1/- per equity share(inclu | ile 7 of the Compar Obligation & Disclos the Board of Direct rd quarter ended on Non Beta-lactam Syr ding share premium |
| ottes:) The quint their The Com The Con d ext 101 | Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended) estandalone unaudited financial results are prepared in accord nts) Rules, 2014 (as amended) and other recognised accounting above standalone unaudited financial results for the quarter e ements) Regulations 2015 (as amended) and were reviewed and meeting held on August 11,2023 A limited review of the above figures for the quarter ended 31 March 2023 are the Balancing ber 2022 which are sujbect to limited review. figures of the previous period have been re-grouped / rearrange Company has Voluntarily adopted the quarterly standalone una npany is mainly engaged in manufacturing of of a wide range o ternal preparations looking into the nature of business company company had made an initial public offering (IPO) of 30,00,000 of per equity share) aggregating to Rs.3330,00/- Lakhs. The aforem The Status of investor's complaints during the year ended on Jun Complaints pending at the beginning of the period Complaints received during the period Complaints received at the end of the period Complaints resolved at the end of the period | practices and policies, inded June 30, 2023 h d recommended by th results has been carri figures between the a ed and / or recasted w uudited financial result of pharmaceutical proc is operating under sin equity shares of face w nentioned equity shar ne 30, 2023 as under; s is RS. 3,330.00 Lakhs | , as applicable have been prepar se Audit Committ feed out by the sta audited figures in wherever consider ts for the quarter ducts such as Nor hgle segment hen value of Rs. 10/- i es of the compar | Prescribed urder Sec ed by the Company ee of the Board and tutory auditors of th respect of full finan ed necessary. ended 30th June 20: n Beta-Lactam (gene ce segment reportin each fully paid up for hy alloted as on 10th Nill 1 1 Nill he are as follows: | tion 133 of the Compani in accordance with Regu thereafter were approve e company cial year and the year-to- 23. rral) tablets, Non Beta-Lan g is not applicable to Cor r cash at a price of Rs. 11 | es Act,2013 read with Ru lation 33 of SEBI (Listing (d and taken on record by date figures up to the thir ctam (general) capsules, f npany. 1/- per equity share(inclu | ile 7 of the Compar Obligation & Disclos the Board of Direct rd quarter ended on Non Beta-lactam Syr ding share premium |
| otes:) The ccou) The equire their) The cem) The 1 On d ext 101 | Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended) estandalone unaudited financial results are prepared in accord nts) Rules, 2014 (as amended) and other recegnised accounting above standalone unaudited financial results for the quarter e ements) Regulations 2015 (as amended) and were reviewed and meeting held on August 11,2023. A limited review of the above figures for the quarter ended 31 March 2023 are the Balancing ber 2022 which are sujbect to limited review. figures of the previous period have been re-grouped / rearrange Company has Voluntarily adopted the quarterly standalone una npany is mainly engaged in manufacturing of of a wide range o ternal preparations looking into the nature of business company company had made an initial public offering (IPO) of 30,00,000 or per equity share) aggregating to Rs.3330,00/- Lakhs. The aforem The Status of investor's complaints during the year ended on Jun Complaints received during the period Complaints received during the period Complaints received at the end of the period Complaints resolved at the end of the period Complaints received at the end of the period Complaints received at the end of the period Complaints pending at the beginning of the period Complaints disposed during the period Complaints pending at the before Net off Issue related expenses 5r. Particulars | practices and policies, inded June 30, 2023 h d recommended by th results has been carri figures between the a ed and / or recasted w audited financial result of pharmaceutical proc is operating under sin equity shares of face v nentioned equity share e 30, 2023 as under: | , as applicable have been prepar ee Audit Committ leed out by the sta audited figures in wherever consider ts for the quarter ducts such as Noi rage segment hen value of Rs. 10/- i es of the compar s. The Object for t Utilised | Prescribed urder Sec ed by the Company ee of the Board and tutory auditors of th respect of full finan ed necessary. ended 30th June 20: n Beta-Lactam (gene ce segment reportin each fully paid up fo ny alloted as on 10th Nill 1 1 Nill he are as follows: Pending to be Utilised | tion 133 of the Compani in accordance with Regu thereafter were approve e company cial year and the year-to- 23. rral) tablets, Non Beta-Lan g is not applicable to Cor r cash at a price of Rs. 11 | es Act,2013 read with Ru lation 33 of SEBI (Listing (d and taken on record by date figures up to the thir ctam (general) capsules, f npany. 1/- per equity share(inclu | ile 7 of the Compar Obligation & Disclos the Board of Direct rd quarter ended on Non Beta-lactam Syr ding share premium |
| otes:) The ccou) The equire their) The cem) The 1 On d ext 101 | Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended) estandalone unaudited financial results are prepared in accord nts) Rules, 2014 (as amended) and other recegnised accounting above standalone unaudited financial results for the quarter e ements) Regulations 2015 (as amended) and were reviewed and meeting held on August 11,2023. A limited review of the above figures for the quarter ended 31 March 2023 are the Balancing ber 2022 which are subect to limited review. figures of the previous period have been re-grouped / rearrange Company has Voluntarily adopted the quarterly standalone una npany is mainly engaged in manufacturing of of a wide range o ternal preparations looking into the nature of business company company had made an initial public offering (IPO) of 30,00,000 o per equity share) aggregating to Rs.3330,00/- Lakhs. The aforem The Status of investor's complaints during the year ended on Jun Complaints received during the period Complaints received during the period Complaints received during the period Complaints received at the end of the period The Proceeds from the IPO before Net off Issue related expensese Sr. Particulars a To Meet Working Capital Requirements b Investment in Subsidiary Upgradation / Construction of Existing | practices and policies, inded June 30, 2023 h d recommended by th results has been carri figures between the a ed and / or recasted w isudited financial result of pharmaceutical proc is operating under sin equity shares of face w nentioned equity share e 30, 2023 as under: | , as applicable have been prepar se Audit Committ led out by the sta audited figures in wherever consider ts for the quarter ducts such as Nor- rage segment hen value of Rs. 10/- i es of the compar s. The Object for t Utilised 1,080.00 700.00 | Prescribed urder Sec ed by the Company ee of the Board and tutory auditors of th respect of full finan ed necessary. ended 30th June 20: n Beta-Lactam (gene ce segment reportin each fully paid up fo ny alloted as on 10th Nill 1 1 Nill he are as follows: Pending to be Utilised Nil Nil Nil | tion 133 of the Compani in accordance with Regu thereafter were approve e company cial year and the year-to- 23. rral) tablets, Non Beta-Lan g is not applicable to Cor r cash at a price of Rs. 11 | es Act,2013 read with Ru lation 33 of SEBI (Listing (d and taken on record by date figures up to the thir ctam (general) capsules, f npany. 1/- per equity share(inclu | ile 7 of the Compar Obligation & Disclos the Board of Direct rd quarter ended on Non Beta-lactam Syl ding share premium |
| ottes:) The quint their The Com The Con d ext 101 | Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended) e standalone unaudited financial results are prepared in accord nts) Rules, 2014 (as amended) and other recognised accounting in above standalone unaudited financial results for the quarter e ements) Regulations 2015 (as amended) and were reviewed and meeting held on August 11,2023 A limited review of the above figures for the quarter ended 31 March 2023 are the Balancing ber 2022 which are sujbect to limited review. figures of the previous period have been re-grouped / rearrange Company has Voluntarily adopted the quarterly standalone una npany is mainly engaged in manufacturing of of a wide range o ternal preparations looking into the nature of business company company had made an initial public offering (IPO) of 30,00,000 of per equity share) aggregating to Rs.3330,00/- Lakhs. The aforem The Status of investor's complaints during the year ended on Jun Complaints pending at the beginning of the period Complaints received during the period Complaints received at the end of the period Complaints resolved at the end of the period Complaints resolved at the end of the period Complaints resolved at the off Issue related expenses Sr. Particulars a To Meet Working Capital Requirements b Investment in Subsidiary. Cuppardation / Construction of Existing (New Building in the Existing Premises | practices and policies, inded June 30, 2023 h d recommended by th results has been carri figures between the a ed and / or recasted w audited financial result of pharmaceutical proc is operating under sin equity shares of face w nentioned equity shar to 30, 2023 as under:- s is RS. 3,330.00 Lakhs Planned As per Prospectus 1,080.00 700.00 590.01 | , as applicable have been prepar ne Audit Committ (ed out by the sta- audited figures in wherever consider ts for the quarter ducts such as Noi rgle segment hen value of Rs. 10/- i es of the compar- son the compar- son the Compar- tion to the compar- son the Compar- tion to the compar- tion to the compar- son the Compar- tion to the compar- son the Compar- son the Compar- tion to the compar- son the Compar- son the Compar- son the Compar- son the Compar- son the Compar- tion to the compar- son the Compar- | Prescribed urder Sec ed by the Company ee of the Board and tutory auditors of th respect of full finan ed necessary. ended 30th June 20: n Beta-Lactam (gene ce segment reportir each fully paid up for ny alloted as on 10th Nill 1 1 Nill Nill Nil Nil Nil Nil | tion 133 of the Compani in accordance with Regu thereafter were approve e company cial year and the year-to- 23. rral) tablets, Non Beta-Lan g is not applicable to Cor r cash at a price of Rs. 11 | es Act,2013 read with Ru lation 33 of SEBI (Listing (d and taken on record by date figures up to the thir ctam (general) capsules, f npany. 1/- per equity share(inclu | ile 7 of the Compar Obligation & Disclos the Board of Direct rd quarter ended on Non Beta-lactam Syl ding share premium |
| otes:) The cccou) The equiriter their) The) The 1 On 1 On | Basic /Diluted earnings per share (In INR) (not annualised, for the quarter ended) estandalone unaudited financial results are prepared in accord nts) Rules, 2014 (as amended) and other recegnised accounting: above standalone unaudited financial results for the quarter e ements) Regulations 2015 (as amended) and were reviewed and meeting held on August 11,2023 A limited review of the above figures for the quarter ended 31 March 2023 are the Balancing ber 2022 which are sujbect to limited review. figures of the previous period have been re-grouped / rearrange Company has Voluntarily adopted the quarterly standalone una npany is mainly engaged in manufacturing of of a wide range o ternal preparations looking into the nature of business company company had made an initial public offering (IPO) of 30,00,000 of per equity share) aggregating to Rs.3330,00/- Lakhs. The aforem The Status of investor's complaints during the year ended on Jun Complaints received during the period Complaints received during the period Complaints resolved at the end of the period Complaints resolved at the end of the period Complaints resolved at the end of the guine 5r. Particulars a To Meet Working Capital Requirements b Investment in Subsidiary c Upgradation / Construction of Existing | practices and policies, inded June 30, 2023 h d recommended by th results has been carri figures between the a ed and / or recasted w isudited financial result of pharmaceutical proc is operating under sin equity shares of face w nentioned equity share e 30, 2023 as under: | , as applicable have been prepar se Audit Committ led out by the sta audited figures in wherever consider ts for the quarter ducts such as Nor- rage segment hen value of Rs. 10/- i es of the compar s. The Object for t Utilised 1,080.00 700.00 | Prescribed urder Sec ed by the Company ee of the Board and tutory auditors of th respect of full finan ed necessary. ended 30th June 20: n Beta-Lactam (gene ce segment reportin each fully paid up fo ny alloted as on 10th Nill 1 1 Nill he are as follows: Pending to be Utilised Nil Nil Nil | tion 133 of the Compani in accordance with Regu thereafter were approve e company cial year and the year-to- 23. rral) tablets, Non Beta-Lan g is not applicable to Cor r cash at a price of Rs. 11 | es Act,2013 read with Ru lation 33 of SEBI (Listing (d and taken on record by date figures up to the thir ctam (general) capsules, f npany. 1/- per equity share(inclu | ile 7 of the Compar Obligation & Disclos the Board of Direct rd quarter ended on Non Beta-lactam Syl ding share premium |

For & on behalf of Sotac Pharmaceuticals Limited

Droph

Sharad Patel DIN:07252252 Chairman & Managing Director

Place : Ahmedabad Date : 11th August, 2023



CA Keyur Shah FCA, B.Com, ISA,

Limited Review Report on unaudited consolidated financial results of Sotac Pharmaceutical Certified Limited for the Quarter ended 30 June 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To, The Board of Directors of, Sotac Pharmaceutical Limited (Formerly Known As Sotac Pharmaceutical Private Limited)

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results ("the Statement") of **Sotac Pharmaceutical Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2023, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down as per Accounting Standards, Prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

1. Sotac Pharmaceutical Limited ("Parent")

SHAH

- 2. Sotac Healthcare Private Limited ("Subsidiary")
- 3. Sotac Lifesciences Private Limited ("Subsidiary")
- 4. Sotac Research Private Limited ("Subsidiary")

Based on our review conducted and procedures performed as stated in above and based on the statement provided by the Management related to Parent & Subsidiary, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of

303, Shitiratna, B/s. Radisson Biu Hote Mr. Karchvati Circle, Ambawadi, Ahmedabad-380006. Gujarat, INDIA. Ph. : +91 79 48999595, W. : +91 999 8484 564 • Website : www.keyurshahca.com E-mail : keyur@keyurshahca.com.cca.keyurshah2015@gmail.com Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We did not review the interim financial statements / financial information / financial results of Subsidiaries i.e. Sotac Healthcare Private Limited ("Subsidiary")/ Sotac Lifesciences Private Limited ("Subsidiary")/ Sotac Research Private Limited ("Subsidiary") included in the consolidated unaudited financial results, whose interim financial statements / financial information / financial results reflect total revenues of Rs. 101.89 Lakhs and total net profit/(loss) after tax of Rs. (22.16) Lakhs for the quarter ended June 30, 2023, respectively, as considered in the consolidated unaudited financial results have not been reviewed by us. These interim financial statements / financial information / financial results have been reviewed by the Auditor of respective subsidiary company and provided by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiary is based solely on the reports provided by the Management and the procedures performed by us as stated in above paragraph.

Our conclusion on the statement is not modified in respect of the above matters.

ALP NO

DACCO

For, Keyur Shah & Co. Chartered Accountants F.R.No. 141173W

Keyur Shah Proprietor M. No. 153774 UDIN: -23153774BGWLXX1531

Date: - 11th August, 2023 Place: - Ahmedabad

| | CONSOLIDATED ST | | | | | | |
|---|--|--|--|---|--|---|---|
| | | | | | | NR in Lakhs unless other | the second se |
| Sr no. | Particulars | | | 30.06.2023 Unaudited | Quarter ended 31.03.2023 Audited | 30.06.2022 Unaudited | Year ended 31.03.2023 Audited |
| 1) | REVENUE FROM OPERATIONS | | | 2496.70 | 1808.39 | 1986.96 | 7748.3 |
| 11) 111) | OTHER INCOME TOTAL REVENUE (1 + II) | | | 22.99 2519.69 | 13.62 1822.01 | 6.93 1993.89 | 34.9 |
| IV) | EXPENSES | | | 2515.05 | 1011.01 | 1999.09 | 7703.1 |
| a) | Cost of Material Consumed | | | 1787.67 | 1473.34 | 1605.43 | 6115.2 |
| | Purchase of Stock-in-Trade Changes in Inventories of Finished Goods/ Work-In-Prop | sease / Stack in Tendo | | 8.05 (26.16) | 13.00 (291.88) | 2.32 (61.59) | 52.6 (440.9 |
| | Employee Benefit Expenses | gressy stock in trade | | 97.78 | 112.39 | 88.39 | 422.7 |
| | Finance Costs | | | 45.82 | 64.10 | 29.47 | 197.5 |
| | Depreciation and Amortisation Expense Other Expenses | | | 60.44 395.77 | 60.62 259.73 | 49.96 160.74 | 227.3 |
| | TOTAL EXPENSES (IV) | | | 2369.37 | 1691.30 | 1874.72 | 7448.0 |
| V) | PROFIT/(LOSS) BEFORE EXCEPTIONAL & EXTRAORDINA | RY ITEMS & TAX (III - I | V) | 150.32 | 130.71 | 119.17 | 334.6 |
| (1) | Exceptional/Prior Period Items | | | - | | | 58.0 |
| (11) | PROFIT BEFORE EXTRAORDINARY ITEMS & TAX (V-VI) | | | 150.32 | 130.71 | 119.17 | 392.6 |
| (111) | Extraordinary Items | | | | 14 | - | |
| X) | PROFIT BEFORE TAX (VII-VIII) | | | 150.32 | 130.71 | 119.17 | 392.6 |
| | TAX EXPENSE | | | | | | |
| a) | Current Tax Deferred Tax | | | 45.92 | 48.87 | 70.08 | 168.3 |
| | | | | 6.00 | (21.73) | (4.57) | (4.3) |
| | TOTAL TAX EXPENSE (X) | | | 51.92 | 27.14 | 65.51 | 164.0 |
| | PROFIT / (LOSS) FOR THE PERIOD/YEAR (IX-X) | | - | 98.40 | 103.57 | 53.66 | 228.6 |
| | Paidup Equity Share Capital (Face value Rs 10 each) | | | 1105.00 | 805.00 | 230.00 | 805.0 |
| 300) | Reserve & Surplus (Excluding Revaluation Reserve) | | | | | | 193.8 |
| nn 1 | EARNINGS PER EQUITY SHARE-BASIC/DILUTED | | | | | | |
| 10) | | | | | | | |
| otes:] Th ompa] Th isclos oard] Th | e consolidated unaudited financial results are prepared anies (Accounts) Rules, 2014 (as amended) and other rec e above consolidated unaudited financial results for the sure Requirements) Regulations 2015 (as amended) and of Directors in their meeting held on August 11,2023, A e figures for the quarter ended 31 March 2023 are the | ognised accounting pra quarter ended June 30 were reviewed and rec limited review of the al Balancing figures betw | actices and polic D, 2023 have be commended by t bove results has | ies, as applicable en prepared by the the Audit Committee been carried out by | Company in accordance v e of the Board and thereal the statutory auditors of i | vith Regulation 33 of SEB fter were approved and t the company - | ad with Rule 7 of Il (Listing Obligation aken on record by |
| otess] The pompa] The sclose pard] The ded] The] Con rup] The are] the are] the are] The sclose bard] The sclose] The sclose] The sclose] The sclose] The sclose] The sclose] The sclose] The sclose] The] The sclose] The sclose] The] The sclose] The] The sclose] The] The [The [The [The [The [The [The [The [The [The [The [The [The [The | (not annualised, for the quarter ended) e consolidated unaudited financial results are prepared anies (Accounts) Rules, 2014 (as amended) and other rec e above consolidated unaudited financial results for the sure Requirements) Regulations 2015 (as amended) and of Directors in their meeting held on August 11,2023, A e figures for the quarter ended 31 March 2023 are the on 31 december 2022 which are sujbect to limited revie e figures of the previous period have been re-grouped / r e Company has Voluntarily adopted the quarterly consoli mpany is mainly engaged in manufacturing of of a wide i and external preparations looking into the nature of busi Holding company had made an initial public offering (IP oremium of Rs. 101 per equity share) aggregating to Rs. m on 13th April, 2023. Sotac Lifesciences Private Limited "The Subsidiary" of th | ognised accounting pra- quarter ended June 30 were reviewed and rec limited review of the al Balancing figures betw w. rearranged and / or rec dated unaudited finan- range of pharmaceutic iness company is opera- to) of 30,00,000 equity 3330.00/- Lakhs. The a he Holding company h | actices and polic D, 2023 have be commended by I bove results has een the audited asted wherever cial results for th al products such ting under singl shares of face is forementioned ad made Right I | tandards Prescribed ites, as applicable en prepared by the the Audit Committee been carried out by d figures in respect o considered necessar he quarter ended 301 nas Non Beta-Lactam e segment hence se value of Rs. 10/- eac equity shares of the ssue of 99,50,000 eq | urder Section 133 of the Company in accordance v e of the Board and thereal the statutory auditors of of full financial year and the ry. th June 2023. In (general) tablets, Non Be gment reporting is not ap h fully paid up for cash at e company alloted as on utity shares of face value of | e Companies Act,2013 re with Regulation 33 of SEB fter were approved and t the company . he year-to-date figures u eta-Lactam (general) caps plicable to Company. a price of Rs. 11/- per 10th April, 2023 and got of Rs. 10/- each fully paid | ad with Rule 7 of II (Listing Obligation aken on record by p to the third quar ules, Non Beta-lact equity share(includ listed on NSE Eme |
| otes:] The board] The isclosion coard] The isclosion] The] T | Inot annualised, for the quarter ended) e consolidated unaudited financial results are prepared anies (Accounts) Rules, 2014 (as amended) and other rec e above consolidated unaudited financial results for the sure Requirements) Regulations 2015 (as amended) and of Directors in their meeting held on August 11,2023, Al e figures for the quarter ended 31 March 2023 are the on 31 december 2022 which are sujbect to limited revie figures of the previous period have been re-grouped / r c Company has Voluntarily adopted the quarterly consoli mpany is mainly engaged in manufacturing of of a wide is Holding company had made an initial public offering (IP premium of Rs. 101 per equity share) aggregating to Rs. m on 13th April, 2023. Sotac Lifesciences Private, Limited "The Subsidiary" of tl 10/- per equity share (Security Premium- NIL) aggregating The Status of investor's complaints during ine year ende | ognised accounting pra- guarter ended June 30 were reviewed and rec limited review of the al Balancing figures betw w. rearranged and / or rec dated unaudited finan- range of pharmaceutic- iness company is opera (O) of 30,00,000 equity 3330.00/- Lakhs. The a he Holding company h g to Rs.99.50/- Lakhs. T | actices and polic p), 2023 have be commended by I boove results has een the audited asted wherever cial results for th al products such ting under single shares of face forementioned ad made Right I he abovemention | tandards Prescribed ties, as applicable en prepared by the the Audit Committee been carried out by d figures in respect o considered necessar he quarter ended 300 n as Non Beta-Lactar e segment hence se value of Rs. 10/- eac equity shares of the ssue of 99,50,000 eq oned right equity sha | urder Section 133 of the Company in accordance v e of the Board and thereal the statutory auditors of of full financial year and the ry. th June 2023. In (general) tablets, Non Be gment reporting is not ap h fully paid up for cash at e company alloted as on utity shares of face value of | e Companies Act,2013 re with Regulation 33 of SEB ther were approved and t the company . he year-to-date figures u eta-Lactam (general) caps plicable to Company. a price of Rs. 111/- per 10th April, 2023 and got of Rs. 10/- each fully paid r, 2023. | ad with Rule 7 of II (Listing Obligation aken on record by p to the third quar ules, Non Beta-lact equity share(includ listed on NSE Eme up for cash at a pr |
| otes:] Thi ompa] Thi isclosed] Thi isclosed] Thi anded] Thi anded] Thi are r atfor]The are r atfor] The are r atfor] Thi atformation] Thi] Thi | (not annualised, for the quarter ended) e consolidated unaudited financial results are prepared anies (Accounts) Rules, 2014 (as amended) and other rec e abave consolidated unaudited financial results for the sure Requirements) Regulations 2015 (as amended) and of Directors in their meeting held on August 11,2023, A i figures for the quarter ended 31 March 2023 are the on 31 december 2022 which are sujbect to limited revie a figures of the previous period have been re-grouped / r e Company has Voluntarily adopted the quarterly consoli mpany is mainly engaged in manufacturing of of a wide i and external preparations looking into the nature of busi Holding company had made an initial public offering (IP) premium of Rs. 101 per equity share) aggregating to Rs. m on 13th April, 2023. Sotac Lifesciences Private Limited "The Subsidiary" of tl 10/- per equity share (Security Premium- NIL) aggregating | ognised accounting pra- guarter ended June 30 were reviewed and rec limited review of the al Balancing figures betw w. rearranged and / or rec dated unaudited finan- range of pharmaceutic- iness company is opera (O) of 30,00,000 equity 3330.00/- Lakhs. The a he Holding company h g to Rs.99.50/- Lakhs. T | actices and polic p), 2023 have be commended by I boove results has een the audited asted wherever cial results for th al products such ting under single shares of face forementioned ad made Right I he abovemention | tandards Prescribed ites, as applicable en prepared by the the Audit Committee been carried out by d figures in respect o considered necessar he quarter ended 301 nas Non Beta-Lactam e segment hence se value of Rs. 10/- eac equity shares of the ssue of 99,50,000 eq | urder Section 133 of the Company in accordance v e of the Board and thereal the statutory auditors of of full financial year and the ry. th June 2023. In (general) tablets, Non Be gment reporting is not ap h fully paid up for cash at e company alloted as on utity shares of face value of | e Companies Act,2013 re with Regulation 33 of SEB fter were approved and t the company . he year-to-date figures u eta-Lactam (general) caps plicable to Company. a price of Rs. 11/- per 10th April, 2023 and got of Rs. 10/- each fully paid | ad with Rule 7 of II (Listing Obligation aken on record by p to the third quar ules, Non Beta-lact equity share(includ listed on NSE Eme up for cash at a pr |
| otes:] The ompa- solority] The solority] The aded] The aded] The atformation I The afformation I The afformation I The afformation I The I | Inot annualised, for the quarter ended) e consolidated unaudited financial results are prepared anies (Accounts) Rules, 2014 (as amended) and other rec e above consolidated unaudited financial results for the sure Requirements) Regulations 2015 (as amended) and of Directors in their meeting held on August 11,2023, A is figures for the quarter ended 31 March 2023 are the on 31 december 2022 which are sujbect to limited revie - figures of the previous period have been re-grouped / r c company has Voluntarily adopted the quarterly consoli mpany is mainly engaged in manufacturing of of a wide i and external preparations looking into the nature of busi Holding company had made an initial public offering (IP premium of Rs. 101 per equity share) aggregating to Rs. m on 13th April, 2023. Sotac Lifesciences Private Limited "The Subsidiary" of th 10/- per equity share (Security Premium- NIL) aggregating the Status of investor's complaints during the year ende Complaints pendied at the beginning of the period Complaints disposed during the period | ognised accounting pra- guarter ended June 30 were reviewed and rec limited review of the al Balancing figures betw w. rearranged and / or rec dated unaudited finan- range of pharmaceutic- iness company is opera (O) of 30,00,000 equity 3330.00/- Lakhs. The a he Holding company h g to Rs.99.50/- Lakhs. T | actices and polic p), 2023 have be commended by I boove results has een the audited asted wherever cial results for th al products such ting under single shares of face forementioned ad made Right I he abovemention | tandards Prescribed ties, as applicable then prepared by the the Audit Committee been carried out by d figures in respect o considered necessar he quarter ended 300 n as Non Beta-Lactar e segment hence se value of Rs. 10/- eac equity shares of the ssue of 99,50,000 eq oned right equity sha Nill 1 1 | urder Section 133 of the Company in accordance v e of the Board and thereal the statutory auditors of of full financial year and the ry. th June 2023. In (general) tablets, Non Be gment reporting is not ap h fully paid up for cash at e company alloted as on utity shares of face value of | e Companies Act,2013 re with Regulation 33 of SEB ther were approved and t the company . he year-to-date figures u eta-Lactam (general) caps plicable to Company. a price of Rs. 111/- per 10th April, 2023 and got of Rs. 10/- each fully paid r, 2023. | ad with Rule 7 of II (Listing Obligation aken on record by p to the third quar ules, Non Beta-lact equity share(includ listed on NSE Eme up for cash at a pr |
| otes:] The ompa- solority] The solority] The aded] The aded] The atformation I The afformation I The afformation I The afformation I The I | (not annualised, for the quarter ended) e consolidated unaudited financial results are prepared anies (Accounts) Rules, 2014 (as amended) and other rec e above consolidated unaudited financial results for the sure Requirements) Regulations 2015 (as amended) and of Directors in their meeting held on August 11,2023, A e figures for the quarter ended 31 March 2023 are the on 31 december 2022 which are sujbect to limited revie e figures of the previous period have been re-grouped / r e Company has Voluntarily adopted the quarterly consoli mpany is mainly engaged in manufacturing of of a wide i and external preparations looking into the nature of busi Holding company had made an initial public offering (IP premium of Rs. 101 per equity share) aggregating to Rs. m on 13th April, 2023. Sotac Lifesciences Private Limited "The Subsidiary" of th 10/- per equity share (Security Premium - NIL) aggregating The Status of investor's complaints during the year ende Complaints pending at the beginning of the period Complaints disposed during the period Complaints resolved at the end of the period | ognised accounting pra- guarter ended June 30 were reviewed and rec limited review of the al Balancing figures betw w. rearranged and / or rec dated unaudited finan- range of pharmaceutic- iness company is opera (O) of 30,00,000 equity 3330.00/- Lakhs. The a he Holding company h g to Rs.99.50/- Lakhs. T | actices and polic D, 2023 have be commended by to bove results has een the audited asted wherever cial results for th al products such ting under single shares of face of forementioned ad made Right I he abovemention under: | tandards Prescribed ties, as applicable en prepared by the the Audit Committee been carried out by d figures in respect o considered necessar he quarter ended 300 n as Non Beta-Lactar e value of Rs. 10/- eac equity shares of the ssue of 99,50,000 eq oned right equity sha Nill 1 1 Nill 1 1 Nill | urder Section 133 of the Company in accordance we of the Board and thereal the statutory auditors of i of full financial year and the ry. (a (general) tablets, Non Be gment reporting is not app h fully paid up for cash at e company alloted as on uuity shares of face value of the alloted as on 11th May | e Companies Act,2013 re with Regulation 33 of SEB fter were approved and t the company . he year-to-date figures u eta-Lactam (general) caps plicable to Company. a price of Rs. 11/- per 10th April, 2023 and got of Rs. 10/- each fully paid t, 2023. | ad with Rule 7 of II (Listing Obligation aken on record by p to the third quar ules, Non Beta-lact equity share(includ listed on NSE Eme up for cash at a pr |
| otes:] The mpaard] The ided] The] The I The I The Rs. : [] | Inot annualised, for the quarter ended) e consolidated unaudited financial results are prepared anies (Accounts) Rules, 2014 (as amended) and other rec e abave consolidated unaudited financial results for the sure Requirements) Regulations 2015 (as amended) and of Directors in their meeting held on August 11,2023, A e figures for the quarter ended 31 March 2023 are the on 31 december 2022 which are sujbect to limited revice a figures for the previous period have been re-grouped / r e Company has Voluntarily adopted the quarterly consoli mpany is mainly engaged in manufacturing of of a wide i and external preparations looking into the nature of busi Holding company had made an initial public offering (IP premium of Rs. 101 per equity share) aggregating to Rs. m on 13th April, 2023. Sotac Lifesciences Private Limited "The Subsidiary" of tI 10/- per equity share (Security Premium- NIL) aggregating The Status of investor's complaints during the period Complaints received during the period Complaints received at the end of the period List of the Entities Consolidated in the Statement: Name of the Subsidiaries Companies | ognised accounting pra guarter ended June 30 were reviewed and rec limited review of the al Balancing figures betw w. rearranged and / or rec idated unaudited finan- range of pharmaceutic- iness company is opera (O) of 30,00,000 equity 3330.00/- Lakhs. The a he Holding company h g to Rs.99.50/- Lakhs. T d on June 30,2023 as t Relationship Subsidary | actices and polic D, 2023 have be commended by to bove results has een the audited asted wherever cial results for th al products such ting under single shares of face of forementioned ad made Right I he abovemention under: | tandards Prescribed ties, as applicable ten prepared by the the Audit Committee been carried out by d figures in respect of considered necessar he quarter ended 300 n as Non Beta-Lactar e segment hence seg- equity shares of the ssue of 99,50,000 eq- oned right equity shares Nill 1 1 1 Nill f Holding as on 30-06-2023 71.00 | urder Section 133 of the Company in accordance v of the Board and thereal the statutory auditors of i of full financial year and the ry. th June 2023. In (general) tablets, Non Be gment reporting is not ap h fully paid up for cash at e company alloted as on uity shares of face value of the alloted as on 11th May Voting Power Either Dir through Subs Directi | e Companies Act,2013 re vith Regulation 33 of SEB fter were approved and t the company . he year-to-date figures u eta-Lactam (general) caps plicable to Company. a price of Rs. 111/- per 10th April, 2023 and got of Rs. 10/- each fully paid r, 2023. ectly or Indirectly idaries y | ad with Rule 7 of II (Listing Obligation aken on record by p to the third quar ules, Non Beta-lact equity share(includ listed on NSE Eme up for cash at a pr |
| otes:] The mpaard] The ded] The I The I The Rs. :]] | (not annualised, for the quarter ended) e consolidated unaudited financial results are prepared anies (Accounts) Rules, 2014 (as amended) and other rec e above consolidated unaudited financial results for the sure Requirements) Regulations 2015 (as amended) and of Directors in their meeting held on August 11,2023, Al e figures for the quarter ended 31 March 2023 are the on 31 december 2022 which are sujbect to limited revie e figures of the previous period have been re-grouped / r e Company has Voluntarily adopted the quarterly consoli mpany is mainly engaged in manufacturing of of a wide i and external preparations looking into the nature of busi Floding company had made an initial public offering (IP oremium of Rs. 101 per equity share) aggregating to Rs. m on 13th April, 2023. Sotac Lifesciences Private Limited "The Subsidiary" of th 10/- per equity share (Security Premium - NL) aggregating The Status of investor's complaints during the year ende Complaints received during the period Complaints resolved at the end of the period Complaints resolved at the end of the period List of the Entities Consolidated in the Statement: Name of the Subsidiaries Companies | ognised accounting pra- guarter ended June 30 were reviewed and rec limited review of the al Balancing figures betw w. rearranged and / or rec dated unaudited finan- range of pharmaceutic iness company is opera '0) of 30,00,000 equity 3330.00/- Lakhs. The a he Holding company h g to Rs.99.50/- Lakhs. T d on June 30,2023 as t Relationship | actices and polic D, 2023 have be commended by to bove results has een the audited asted wherever cial results for th al products such ting under single shares of face of forementioned ad made Right I he abovemention under: | tandards Prescribed ties, as applicable ten prepared by the the Audit Committee been carried out by d figures in respect of considered necessar- the quarter ended 301 nas Non Beta-Lactam e segment hence se value of Rs. 10/- eac equity shares of the ssue of 99,50,000 eq oned right equity sha Nill 1 1 Nill 1 1 Nill f Holding as on 30-06-2023 | urder Section 133 of the Company in accordance v e of the Board and thereal the statutory auditors of of full financial year and the ry. th June 2023. In (general) tablets, Non Be gment reporting is not ap h fully paid up for cash at e company alloted as on juity shares of face value (are alloted as on 11th May Voting Power Either Dir through Subs | e Companies Act,2013 re vith Regulation 33 of SEB fter were approved and t the company . he year-to-date figures u eta-Lactam (general) caps plicable to Company. a price of Rs. 111/- per 10th April, 2023 and got of Rs. 10/- each fully paid r, 2023. | ad with Rule 7 of II (Listing Obligation aken on record by p to the third quai ules, Non Beta-lact equity share(includ listed on NSE Eme up for cash at a pi |
| otess:] Thi mpa aded] The ided] The ided] The I The Rs. 1 [] [] []]]]]]]]]]]]] | Inot annualised, for the quarter ended) e consolidated unaudited financial results are prepared anies (Accounts) Rules, 2014 (as amended) and other rec e above consolidated unaudited financial results for the sure Requirements) Regulations 2015 (as amended) and of Directors in their meeting held on August 11,2023, A i e figures for the quarter ended 31 March 2023 are the on 31 december 2022 which are sujbect to limited revie e figures of the previous period have been re-grouped / r e company has Voluntarily adopted the quarterly consoli mpany is mainly engaged in manufacturing of of a wider and external preparations looking into the nature of busi Holding company had made an initial public offering (IP premium of Rs. 101 per equity share) aggregating to Rs. m on 13th April, 2023. Sotac Lifesciences Private Limited "The Subsidiary" of th IO/- per equity share (Security Premium- NIL) aggregating Complaints pending the beginning of the period Complaints received during t | ognised accounting pra guarter ended June 30 were reviewed and rec limited review of the al Balancing figures betw w. rearranged and / or rec idated unaudited finan- range of pharmaceutic- iness company is opera- ro() of 30,00,000 equity 3330.00/- Lakhs. The a he Holding company h g to Rs.99.50/- Lakhs. T d on June 30 ,2023 as t Relationship Subsidary Subsidary Subsidary | actices and polic D, 2023 have be commended by I bove results has een the audited asted wherever cial results for th al products such ting under single shares of face is forementioned ad made Right I the abovementioned ad made Right I the abovementioned a | standards Prescribed lies, as applicable en prepared by the the Audit Committee been carried out by d figures in respect of considered necessar- he quarter ended 301 nas Non Beta-Lactam e segment hence seg- value of Rs. 10/- eac equity shares of the ssue of 99,50,000 eq- oned right equity shares Nill 1 1 Nill 1 1 1 Nill 1 1 1 1 1 1 1 1 1 1 1 1 1 | urder Section 133 of the Company in accordance v e of the Board and thereat the statutory auditors of of full financial year and the ry. th June 2023. I (general) tablets, Non Be gment reporting is not ap h fully paid up for cash at e company alloted as on juity shares of face value of the alloted as on 11th May Voting Power Either Dir through Subs Directi Direct | e Companies Act,2013 re vith Regulation 33 of SEB fter were approved and t the company . he year-to-date figures u eta-Lactam (general) caps plicable to Company. a price of Rs. 111/- per 10th April, 2023 and got of Rs. 10/- each fully paid r, 2023. | ad with Rule 7 of II (Listing Obligation aken on record by p to the third quar ules, Non Beta-lact equity share(includ listed on NSE Eme up for cash at a pr |
| otess:] Thi mpa aded] The ided] The ided] The I The Rs. 1 [] [] []]]]]]]]]]]]] | Inot annualised, for the quarter ended) e consolidated unaudited financial results are prepared anies (Accounts) Rules, 2014 (as amended) and other rec e above consolidated unaudited financial results for the sure Requirements) Regulations 2015 (as amended) and of Directors in their meeting held on August 11,2023, A i e figures for the quarter ended 31 March 2023 are the on 31 december 2022 which are sujbect to limited revie + figures of the previous period have been re-grouped / r e company has Voluntarily adopted the quarterly consoli mpany is mainly engaged in manufacturing of a wide + e dom and external preparations looking into the nature of busi Holding company had made an initial public offering (IP premium of Rs. 101 per equity share) aggregating to Rs. m on 13th April, 2023. Sotac Lifesciences Private Limited "The Subsidiary" of tl 10/- per equity share (Security Premium- NIL) aggregating The Status of investor's complaints during the period Complaints received during the period Complaints resolved at the end of the period Complaints resolved at the end of the Statement: Name of the Subsidaries Companies Sotac Lifesciences Private Limited Sotac Research Private Limited Sotac Lifesciences Private Limited Sotac Lifesciences Private Limited Sotac Research Private Limited Sotac Lifesciences Private Limited Sotac Researc | ognised accounting pra guarter ended June 30 were reviewed and rec limited review of the al Balancing figures betw w. rearranged and / or rec idated unaudited finan- range of pharmaceutic- iness company is opera- ro() of 30,00,000 equity 3330.00/- Lakhs. The a he Holding company h g to Rs.99.50/- Lakhs. T d on June 30 ,2023 as t Relationship Subsidary Subsidary Subsidary | actices and polic D, 2023 have be commended by 1 bove results has een the audited asted wherever cial results for th al products such ting under singl shares of face of forementioned ad made Right I he abovemention mder: | standards Prescribed lies, as applicable en prepared by the the Audit Committee been carried out by d figures in respect of considered necessar- he quarter ended 301 nas Non Beta-Lactam e segment hence seg- value of Rs. 10/- eac equity shares of the ssue of 99,50,000 eq- oned right equity shares Nill 1 1 Nill 1 1 1 Nill 1 1 1 1 1 1 1 1 1 1 1 1 1 | urder Section 133 of the Company in accordance v e of the Board and thereat the statutory auditors of of full financial year and the ry. th June 2023. I (general) tablets, Non Be gment reporting is not ap h fully paid up for cash at e company alloted as on juity shares of face value of the alloted as on 11th May Voting Power Either Dir through Subs Directi Direct | e Companies Act,2013 re vith Regulation 33 of SEB fter were approved and t the company . he year-to-date figures u eta-Lactam (general) caps plicable to Company. a price of Rs. 111/- per 10th April, 2023 and got of Rs. 10/- each fully paid r, 2023. | ad with Rule 7 of II (Listing Obligation aken on record by p to the third quai ules, Non Beta-lact equity share(includ listed on NSE Eme up for cash at a pi |
| otess) This is closed in the sector is closed observed) The sector is closed in the sector is closed) The sector) The se | Inot annualised, for the quarter ended) e consolidated unaudited financial results are prepared anies (Accounts) Rules, 2014 (as amended) and other rec e above consolidated unaudited financial results for the sure Requirements) Regulations 2015 (as amended) and of Directors in their meeting held on August 11,2023, A i e figures for the quarter ended 31 March 2023 are the on 31 december 2022 which are sujbect to limited revie + figures of the previous period have been re-grouped / r e company has Voluntarily adopted the quarterly consoli mpany is mainly engaged in manufacturing of of a wide + e company has Voluntarily adopted the quarterly consoli mpany is mainly engaged in manufacturing of a wide + Holding company had made an initial public offering (IP oremium of Rs. 101 per equity share) aggregating to Rs. m on 13th April, 2023. Sotac Lifesciences Private Limited "The Subsidiary" of tl 10/- per equity share (Security Premium- NIL) aggregating The Status of investor's complaints during the period Complaints received during the period Complaints received during the period Complaints resolved at the end of the period Complaints received turing the period Sotac Research Private Limited Sotac Lifesciences Private Limited Sotac Private Limited Sotac Private Limited Sotac Lifesciences Private Limited Sotac Lifesciences Private Limited Sotac Private Limited Sotac Private Limited Sotac Private Limit | ognised accounting pra quarter ended June 30 were reviewed and rec limited review of the al Balancing figures betw w. rearranged and / or rec dated unaudited finan- range of pharmaceutic- iness company is opera (0) of 30,00,000 equity 3330.00/- Lakhs. The he Holding company h g to Rs.99.50/- Lakhs. T d on June 30,2023 as u Relationship Subsidary Subsidary Subsidary Subsidary Subsidary Subsidary Subsidary | actices and polic D, 2023 have be commended by 1 bove results has een the audited asted wherever cial results for th al products such ting under singl shares of face of forementioned ad made Right I he abovemention mder: | tandards Prescribed ites, as applicable ten prepared by the the Audit Committee been carried out by d figures in respect o considered necessar he quarter ended 300 n as Non Beta-Lactar e esegment hence se value of Rs. 10/- eac equity shares of the ssue of 99,50,000 eq oned right equity shares Nill 1 1 Nill f Holding as on 30-06-2023 71.00 100.00 51.26 ect for the are as foll Pending to be Utilised | urder Section 133 of the Company in accordance v e of the Board and thereat the statutory auditors of of full financial year and the ry. th June 2023. I (general) tablets, Non Be gment reporting is not ap h fully paid up for cash at e company alloted as on juity shares of face value of the alloted as on 11th May Voting Power Either Dir through Subs Directi Direct | e Companies Act,2013 re vith Regulation 33 of SEB fter were approved and t the company . he year-to-date figures u eta-Lactam (general) caps plicable to Company. a price of Rs. 111/- per 10th April, 2023 and got of Rs. 10/- each fully paid r, 2023. | ad with Rule 7 of II (Listing Obligation aken on record by p to the third quai ules, Non Beta-lact equity share(includ listed on NSE Eme up for cash at a pi |
| otess) This is closed in the sector is closed observed) The sector is closed in the sector is closed) The sector) The se | Inot annualised, for the quarter ended) e consolidated unaudited financial results are prepared anies (Accounts) Rules, 2014 (as amended) and other rec above consolidated unaudited financial results for the sure Requirements) Regulations 2015 (as amended) and of Directors in their meeting held on August 11,2023, Al e figures for the quarter ended 31 March 2023 are the on 31 december 2022 which are sujbect to limited revies figures of the previous period have been re-grouped / r company has Voluntarily adopted the quarterly consoli mpany is mainly engaged in manufacturing of of a wide r and external preparations looking into the nature of busil Holding company had made an initial public offering (IP oremium of Rs. 101 per equity share) aggregating to Rs. m on 13th April, 2023. Sotac Lifesciences Private Limited "The Subsidiary" of th 10/- per equity share (Security Premium - NIL) aggregating the Status of investor's complaints during the period Complaints received during the period Complaints received during the end of the period Complaints received during the period Complaints received the end of the period Complaints received the end of the period Complaints received the end of the statement: Name of the Subsidaries Companies Sotac Healthcare Private Limited Sotac Lifesciences Private Limited Sotac Research Private Limited Sotac Research Private Limited | ognised accounting pra- guarter ended June 30 were reviewed and rec limited review of the al Balancing figures betw w. rearranged and / or rec dated unaudited finan- range of pharmaceutic. ness company is opera '0) of 30,00,000 equity 3330.00/- Lakhs. The a he Holding company h g to Rs.99.50/- Lakhs. T d on June 30 ,2023 as u Relationship Subsidary Subsidary Subsidary Subsidary xpenses is RS. 3,330.00 Planned As per Prospectus 1,080.00 | actices and polic D, 2023 have be commended by 1 bove results has een the audited asted wherever cial results for th al products such ting under single shares of face of forementioned ad made Right I he abovemention under: | tandards Prescribed ites, as applicable en prepared by the the Audit Committee been carried out by d figures in respect o considered necessar ne quarter ended 301 nas Non Beta-Lactam e segment hence seg- value of Rs. 10/- eac equity shares of the ssue of 99,50,000 eq oned right equity shares Nill 1 Nill 1 Nill 1 Nill f Holding as on 30-06-2023 71.00 100.00 51.26 ect for the are as foll Pending to be Utilised Nill | urder Section 133 of the Company in accordance v e of the Board and thereat the statutory auditors of of full financial year and the ry. th June 2023. I (general) tablets, Non Be gment reporting is not ap h fully paid up for cash at e company alloted as on juity shares of face value of the alloted as on 11th May Voting Power Either Dir through Subs Directi Direct | e Companies Act,2013 re vith Regulation 33 of SEB fter were approved and t the company . he year-to-date figures u eta-Lactam (general) caps plicable to Company. a price of Rs. 111/- per 10th April, 2023 and got of Rs. 10/- each fully paid r, 2023. | ad with Rule 7 of II (Listing Obligation aken on record by p to the third quai ules, Non Beta-lact equity share(includ listed on NSE Eme up for cash at a pi |
| otess) This is closed in the sector is closed observed) The sector is closed in the sector is closed) The sector) The se | Inot annualised, for the quarter ended) e consolidated unaudited financial results are prepared anies (Accounts) Rules, 2014 (as amended) and other rec e above consolidated unaudited financial results for the sure Requirements) Regulations 2015 (as amended) and of Directors in their meeting held on August 11,2023, A i e figures for the quarter ended 31 March 2023 are the on 31 december 2022 which are sujbect to limited revie i figures of the previous period have been re-grouped / r e company has Voluntarily adopted the quarterly consoli mpany is mainly engaged in manufacturing of a wide + e company has Voluntarily adopted the quarterly consoli mpany is mainly engaged in manufacturing of of a wide + de on 13th April, 2023. Sotac Lifesciences Private Limited "The Subsidiary" of tl 10/- per equity share (Security Premium - NIL) aggregating the Status of investor's complaints during the period Complaints resolved at the end of the period Complaints resolved at the end of the period Complaints resolved at the end of the period Sotac Lifesciences Private Limited Sotac Research Private Limited Sotac Lifesciences Private Limited Sotac Research Private Limited Sotac Lifesciences Private Limited Sotac Lifesciences Private Limited Sotac Private Limited Sotac Lifesciences Private Limited Sotac Private | ognised accounting pra- guarter ended June 30 were reviewed and rec limited review of the al Balancing figures betw w. rearranged and / or rec diated unaudited finan- range of pharmaceutic. ness company is opera '0) of 30,00,000 equity 3330.00/- Lakhs. The al he Holding company h g to Rs.99.50/- Lakhs. The d on June 30,2023 as u Relationship Subsidary Subsidary Subsidary Subsidary Subsidary xpenses is RS. 3,330.00 Planned As per Prospectus 1,080.00 700.00 | actices and polic D, 2023 have be commended by 1 bove results has een the audited asted wherever cial results for th al products such ting under single shares of face of forementioned ad made Right I he abovemention under: | tandards Prescribed ites, as applicable en prepared by the the Audit Committee been carried out by d figures in respect o considered necessar ne quarter ended 301 n as Non Beta-Lactar e segment hence se value of Rs. 10/- eac equity shares of the ssue of 99,50,000 eq oned right equity sha Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill | urder Section 133 of the Company in accordance v e of the Board and thereat the statutory auditors of of full financial year and the ry. th June 2023. I (general) tablets, Non Be gment reporting is not ap h fully paid up for cash at e company alloted as on juity shares of face value of the alloted as on 11th May Voting Power Either Dir through Subs Directi Direct | e Companies Act,2013 re vith Regulation 33 of SEB fter were approved and t the company . he year-to-date figures u eta-Lactam (general) caps plicable to Company. a price of Rs. 111/- per 10th April, 2023 and got of Rs. 10/- each fully paid r, 2023. | ad with Rule 7 of I (Listing Obligation aken on record by p to the third quar ules, Non Beta-lact equity share(includ listed on NSE Eme up for cash at a pr |
| otess] The pmpaard] The sclos- pard] The] The are r 1 [The Rs. 1] [] [] []] []]]]]]]]]]]]] | Inot annualised, for the quarter ended) e consolidated unaudited financial results are prepared anies (Accounts) Rules, 2014 (as amended) and other rec e above consolidated unaudited financial results for the sure Requirements) Regulations 2015 (as amended) and of Directors in their meeting held on August 11,2023, Al e figures for the quarter ended 31 March 2023 are the on 31 december 2022 which are sujbect to limited revie e figures of the previous period have been re-grouped / r e company has Voluntarily adopted the quarterly consoli mpany is mainly engaged in manufacturing of a wide i holding company had made an initial public offering (IP poremium of Rs. 101 per equity share) aggregating to Rs. m on 13th April, 2023. Sotac Lifesciences Private Limited "The Subsidiary" of tl 10/- per equity share (Security Premium- NIL) aggregating The Status of investor's complaints during the period Complaints resolved at the end of the period Complaints resolved at the end of the period Complaints resolved at the end of the period Sotac Healthcare Private Limited Sotac Research Private Limited Sotac Research Private Limited Sotac Research Private Limited Sotac Healthcare Private Limited | ognised accounting pra- guarter ended June 30 were reviewed and rec limited review of the al Balancing figures betw w. rearranged and / or rec dated unaudited finan- range of pharmaceutic iness company is opera (0) of 30,00,000 equity 3330.00/- Lakhs. The al- he Holding company h g to Rs.99.50/- Lakhs. The d on June 30,2023 as u Relationship Subsidary Su | actices and polic D, 2023 have be commended by 1 bove results has een the audited asted wherever cial results for th al products such ting under single shares of face of forementioned ad made Right I he abovemention mder: | tandards Prescribed ites, as applicable en prepared by the the Audit Committee been carried out by d figures in respect o considered necessar he quarter ended 301 in as Non Beta-Lactar e segment hence se value of Rs. 10/- eac equity shares of the ssue of 99,50,000 eq oned right equity shares Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 1 1 1 1 1 1 1 1 1 1 1 1 | urder Section 133 of the Company in accordance v e of the Board and thereat the statutory auditors of of full financial year and the ry. th June 2023. I (general) tablets, Non Be gment reporting is not ap h fully paid up for cash at e company alloted as on juity shares of face value of the alloted as on 11th May Voting Power Either Dir through Subs Directi Direct | e Companies Act,2013 re vith Regulation 33 of SEB fter were approved and t the company . he year-to-date figures u eta-Lactam (general) caps plicable to Company. . a price of Rs. 111/- per 10th April, 2023 and got of Rs. 10/- each fully paid r, 2023. | ad with Rule 7 of I (Listing Obligation aken on record by p to the third quar ules, Non Beta-lact equity share(includ listed on NSE Eme up for cash at a pr |
| otes:] The isclosized] The isclosized] The] The] The rup -] The Rs. 1] [] [] [] [] []]]]]]]]]]]]] | Inot annualised, for the quarter ended) e consolidated unaudited financial results are prepared anies (Accounts) Rules, 2014 (as amended) and other rec e above consolidated unaudited financial results for the ure Requirements) Regulations 2015 (as amended) and of Directors in their meeting held on August 11,2023, A i e figures for the quarter ended 31 March 2023 are the on 31 december 2022 which are sujbect to limited revie - figures of the previous period have been re-grouped / r e company has Voluntarily adopted the quarterly consoli mpany is mainly engaged in manufacturing of of a wide + e reail preparations looking into the nature of busi Holding company had made an initial public offering (IP premium of Rs. 101 per equity share) aggregating to Rs. m on 13th April, 2023. Sotac Lifesciences Private Limited "The Subsidiary" of th 10/- per equity share (Security Premium- NIL) aggregating The Status of investor's complaints during the year ende Complaints received during the period Complaints resolved at the end of the period Complaints resolved at the end of the period Sotac Lifesciences Private Limited State Research Private Limited The Proceeds from the IPO before Net off Issue related e Sr. No. Destination of Security Construction of Existing Destination of Construction of Existing Destination Destination of Construction of Existing Destin | ognised accounting pra- guarter ended June 30 were reviewed and rec limited review of the al Balancing figures betw w. rearranged and / or rec diated unaudited finan- range of pharmaceutic. ness company is opera '0) of 30,00,000 equity 3330.00/- Lakhs. The al he Holding company h g to Rs.99.50/- Lakhs. The d on June 30,2023 as u Relationship Subsidary Subsidary Subsidary Subsidary Subsidary xpenses is RS. 3,330.00 Planned As per Prospectus 1,080.00 700.00 | actices and polic D, 2023 have be commended by 1 bove results has een the audited asted wherever cial results for th al products such ting under single shares of face of forementioned ad made Right I he abovemention under: | tandards Prescribed ites, as applicable en prepared by the the Audit Committee been carried out by d figures in respect o considered necessar he quarter ended 301 in as Non Beta-Lactar e segment hence se value of Rs. 10/- eac equity shares of the ssue of 99,50,000 eq oned right equity shares Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 1 1 1 1 1 1 1 1 1 1 1 1 | urder Section 133 of the Company in accordance v e of the Board and thereat the statutory auditors of of full financial year and the ry. th June 2023. I (general) tablets, Non Be gment reporting is not ap h fully paid up for cash at e company alloted as on juity shares of face value of the alloted as on 11th May Voting Power Either Dir through Subs Directi Directi | e Companies Act,2013 re vith Regulation 33 of SEB fter were approved and t the company . he year-to-date figures u eta-Lactam (general) caps plicable to Company. . a price of Rs. 111/- per 10th April, 2023 and got of Rs. 10/- each fully paid r, 2023. | II (Listing Obligation aken on record by p to the third quar ules, Non Beta-lact equity share(includ listed on NSE Emei up for cash at a pr |

Place : Ahmedabad Date : 11th August, 2023 Sharad Patel DIN:07252252 Chairman & Managing Director